Fig. 4From: Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritisForest Plot of ACR50 Treatment Effect Estimates (OR and 95% CrI) from Unadjusted and Adjusted NMAs. Odds ratios estimated from the unadjusted and control group risk adjusted RE NMAs are presented above, focused on comparisons of active interventions versus placebo. Values are reported with corresponding 95% credible intervals. Odds ratios and > 1 favor the active comparator. Downward and upward shifts in treatment effects between NMA approaches can be seen. Legend: ABA = abatacept; ADA = adalimumab; BAR_4 = 4 mg baricitinib; CERTO = certolizumab pegol; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; ETN = etanercept; GOL = golimumab; INF = infliximab; IV = intravenous; MTX = methotrexate; RIT = rituximab; SAR_200 = 200 mg sarilumab; SC = subcutaneous; SSZ = sulfasalazine; STD = standard dose; TOC_4 = tocilizumab 4 mg/kg; TOC_8 = 8 mg/kg tocilizumab; TOF = tofacitinibBack to article page